Cancer Research Landon Prizes for Basic and Translational Cancer Research AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Arango, D.
Right arrow Articles by Augenlicht, L. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Arango, D.
Right arrow Articles by Augenlicht, L. H.
[Cancer Research 61, 4910-4915, June 15, 2001]
© 2001 American Association for Cancer Research

Tumor Biology

c-myc/p53 Interaction Determines Sensitivity of Human Colon Carcinoma Cells to 5-Fluorouracil in Vitro and in Vivo1

Diego Arango2, Georgia A. Corner, Scott Wadler, Paul J. Catalano and Leonard H. Augenlicht

Albert Einstein Cancer Center, Oncology Department, Montefiore Medical Center, Bronx, New York 10467 [D. A., G. A. C., S. W., L. H. A.], and Eastern Cooperative Oncology Group, Statistical Center, Dana-Farber Cancer Institute, Department of Biostatistical Science, Boston, Massachusetts 02115-6084 [P. J. C.]

Colon carcinoma cells overexpress c-myc due to defective Wnt signaling, but only patients whose tumors have an amplified c-myc gene show improved disease-free and overall survival in response to 5-fluoruracil (5FU). Here we show that in two colon carcinoma cell lines that do not have an amplified c-myc gene but differ in their p53 status, high c-myc levels can be further elevated by introducing a c-myc expression vector. Whereas sensitivity to low serum-induced apoptosis was imposed on the parental lines independent of p53 status and was unaffected by further elevation of c-myc, sensitivity to 5FU-induced apoptosis was dependent on both the higher c-myc levels due to the expression vector and wild-type p53 function. The elevated c-myc levels led to higher c-myc transactivation activity in the p53 wild-type cell line, but not in the mutant p53 cell line. The requirement for both elevated c-myc and p53 for 5FU sensitivity was confirmed using antisense c-myc and pifithrin-{alpha}, a specific inhibitor of p53. Finally, the in vitro data predicted that only patients with both amplified c-myc and wild-type p53 in their primary tumors would be responsive to 5FU-based therapy, which was borne out by analysis of tumors from 135 patients entered into a Phase III clinical trial of 5FU-based adjuvant therapy. The data provide significant insight into mechanisms that establish colon tumor cell sensitivity to 5FU, clearly demonstrate the necessity of exercising caution in considering combining novel strategies that target elevated c-myc with standard 5FU-based therapy, and suggest alternative therapeutic strategies that target c-myc and/or p53 mutations in the treatment of colon cancer.




This article has been cited by other articles:


Home page
 Cancer Res.Home page
R. C. Pezo, S. J. Gandhi, L. A. Shirley, R. G. Pestell, L. H. Augenlicht, and R. H. Singer
Single-Cell Transcription Site Activation Predicts Chemotherapy Response in Human Colorectal Tumors
Cancer Res., July 1, 2008; 68(13): 4977 - 4982.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
B. Benassi, G. Zupi, and A. Biroccio
{gamma}-Glutamylcysteine Synthetase Mediates the c-Myc-Dependent Response to Antineoplastic Agents in Melanoma Cells
Mol. Pharmacol., October 1, 2007; 72(4): 1015 - 1023.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
K. Al-Kuraya, H. Novotny, P. Bavi, A. K Siraj, S. Uddin, A. Ezzat, N. A. Sanea, F. Al-Dayel, H. Al-Mana, S. S Sheikh, et al.
HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer
J. Clin. Pathol., July 1, 2007; 60(7): 768 - 772.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Biliran Jr., S. Banerjee, A. Thakur, F. H. Sarkar, A. Bollig, F. Ahmed, J. Wu, Y. Sun, and J. D. Liao
c-Myc Induced Chemosensitization Is Mediated by Suppression of Cyclin D1 Expression and Nuclear Factor-{kappa}B Activity in Pancreatic Cancer Cells
Clin. Cancer Res., May 1, 2007; 13(9): 2811 - 2821.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
E. Grassilli, A. Ballabeni, E. Maellaro, B. Del Bello, and K. Helin
Loss of MYC Confers Resistance to Doxorubicin-induced Apoptosis by Preventing the Activation of Multiple Serine Protease- and Caspase-mediated Pathways
J. Biol. Chem., May 14, 2004; 279(20): 21318 - 21326.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
L. Licitra and J. B. Vermorken
Is there still a role for neoadjuvant chemotherapy in head and neck cancer?
Ann. Onc., January 1, 2004; 15(1): 7 - 11.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. M. Mariadason, D. Arango, Q. Shi, A. J. Wilson, G. A. Corner, C. Nicholas, M. J. Aranes, M. Lesser, E. L. Schwartz, and L. H. Augenlicht
Gene Expression Profiling-Based Prediction of Response of Colon Carcinoma Cells to 5-Fluorouracil and Camptothecin
Cancer Res., December 15, 2003; 63(24): 8791 - 8812.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Fraser, B. M. Leung, X. Yan, H. C. Dan, J. Q. Cheng, and B. K. Tsang
p53 Is a Determinant of X-Linked Inhibitor of Apoptosis Protein/Akt-Mediated Chemoresistance in Human Ovarian Cancer Cells
Cancer Res., November 1, 2003; 63(21): 7081 - 7088.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. A. Clarke, M. L. George, S. Easdale, D. Cunningham, R. I. Swift, M. E. Hill, D. M. Tait, and P. Workman
Molecular Pharmacology of Cancer Therapy in Human Colorectal Cancer by Gene Expression Profiling
Cancer Res., October 15, 2003; 63(20): 6855 - 6863.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. J. Wilson, D. Arango, J. M. Mariadason, B. G. Heerdt, and L. H. Augenlicht
TR3/Nur77 in Colon Cancer Cell Apoptosis
Cancer Res., September 1, 2003; 63(17): 5401 - 5407.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
L. H. Augenlicht, A. Velcich, L. Klampfer, J. Huang, G. Corner, M. Aranes, C. Laboisse, B. Rigas, M. Lipkin, K. Yang, et al.
Application of Gene Expression Profiling to Colon Cell Maturation, Transformation and Chemoprevention
J. Nutr., July 1, 2003; 133(7): 2410S - 2416.
[Abstract] [Full Text] [PDF]

Home page
 J. Nutr.Home page
L. H. Augenlicht, J. M. Mariadason, A. Wilson, D. Arango, W. Yang, B. G. Heerdt, and A. Velcich
Short Chain Fatty Acids and Colon Cancer
J. Nutr., December 1, 2002; 132(12): 3804S - 3808.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. J. Wilson, A. Velcich, D. Arango, A. R. Kurland, S. M. Shenoy, R. C. Pezo, J. M. Levsky, R. H. Singer, and L. H. Augenlicht
Novel Detection and Differential Utilization of a c-myc Transcriptional Block in Colon Cancer Chemoprevention
Cancer Res., November 1, 2002; 62(21): 6006 - 6010.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
L. H. Augenlicht, S. Wadler, and D. Arango
Clinical Response to Fluorouracil and p53
N. Engl. J. Med., October 4, 2001; 345(14): 1065 - 1066.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.